Through a new boxed warning, the FDA is alerting healthcare professionals about a subgroup of patients who cannot effectively metabolize the anti-platelet drug Clopidogrel [Plavix]. These patients, called “poor metabolizers,” have little or no activity of the liver enzyme CYP2C19, …

Reduced Effect from Clopidogrel [Plavix] in “Poor Metabolizer” Patients Read more »